RespireRx Pharmaceuticals Inc (fka RSPI)

[ombowstring]

gfp, I would think that Samyang is going to try to drum up some business in Asia and if they are successful, Cortex would certainly go along with it. An MOU might or might not be binding, but that's irrelevant. The question is how soon might Cortex/Samyang start selling product in Asia.

I'm sure Cortex would get substantial revenues from royalties due to any revenues that Samyang might receive. There might be revenues due to Cortex if the MOU develops into a contractual deal, but I think what is more important is whether or not Samyang can bring either CX1739 or CX1846 to market.